Document Detail


Novel therapies for the treatment of advanced prostate cancer.
MedLine Citation:
PMID:  23322116     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
In recent years, great success has been achieved on many fronts in the treatment of men with metastatic castration-resistant prostate cancer (CRPC), including novel chemotherapeutics, immunotherapies, bone microenvironment-targeted agents, and hormonal therapies. Numerous agents are currently in early-phase clinical trial development for the treatment of advanced prostate cancer. These novel therapies target several areas of prostate tumor biology, including the upregulation of androgen signaling and biosynthesis, critical oncogenic intracellular pathways, epigenetic alterations, and cancer immunology. Importantly, the characterization of the prostate cancer genome offers the potential to exploit conserved genetic alterations, which may increase the efficacy of these targeted therapies. Predictive and prognostic biomarkers are urgently needed to maximize therapeutic efficacy and safety of these promising new treatments options in prostate cancer.
Authors:
J M Clarke; A J Armstrong
Related Documents :
22142566 - Patterns of and hypotheses for infection-related cancers in a chinese population with r...
1892536 - Surgeon's role in diagnostic advances.
24623866 - Capecitabine and gemcitabine (capgem, cg, gemcap) for advanced pancreatic and biliary t...
24818166 - The role of pam4 in the management of pancreatic cancer: diagnosis, radioimmunodetectio...
7635586 - Cancer incidence in a group of workers potentially exposed to ethylene oxide.
22962276 - Role of the human high-affinity copper transporter in copper homeostasis regulation and...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Current treatment options in oncology     Volume:  14     ISSN:  1534-6277     ISO Abbreviation:  Curr Treat Options Oncol     Publication Date:  2013 Mar 
Date Detail:
Created Date:  2013-02-11     Completed Date:  2013-07-23     Revised Date:  2014-03-06    
Medline Journal Info:
Nlm Unique ID:  100900946     Medline TA:  Curr Treat Options Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  109-26     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Androgen Antagonists / therapeutic use*
Humans
Immunotherapy*
Male
Orchiectomy
Prostatic Neoplasms / drug therapy*,  genetics*
Signal Transduction
Steroid 17-alpha-Hydroxylase / antagonists & inhibitors*
Grant Support
ID/Acronym/Agency:
R01 CA127727/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Androgen Antagonists; EC 1.14.99.9/Steroid 17-alpha-Hydroxylase
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Evaluation of the potential for diacetylenes as reporter molecules in 3D micelle gel dosimetry.
Next Document:  Role of Arsenic Trioxide in Acute Promyelocytic Leukemia.